Exhibit 99.1

STEALTH BIOTHERAPEUTICS CORP

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

(unaudited)

	Three months ending March 31,
	2022			2021
Operating expenses:
Research and development	$	7,776		$	6,099
General and administrative		5,298			4,979
Total operating expenses		13,074			11,078
Loss from operations		(13,074	)		(11,078	)
Other income (expense):
Gain from remeasurement of derivative liability		5,476			3,688
Interest income		3			1
Interest expense and other		(541	)		(300	)
Total other income		4,938			3,389
Net loss attributable to ordinary shareholders	$	(8,136	)	$	(7,689	)
Net loss per share attributable to ordinary shareholders — basic and diluted	$	(0.01	)	$	(0.01	)
Weighted average ordinary shares used in net loss per share attributable to ordinary shareholders — basic and diluted		715,444,473			652,807,323

STEALTH BIOTHERAPEUTICS CORP

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

	March 31,			December 31,
	2022			2021
Assets
Current assets:
Cash and cash equivalents	$	33,834		$	47,135
Prepaid expenses and other current assets		2,566			2,467
Total current assets		36,400			49,602
Property and equipment, net		88			97
Deferred financing costs and other non-current assets		427			527
Total assets	$	36,915		$	50,226
Liabilities and shareholders’ deficit
Current liabilities:
Accounts payable	$	4,122		$	3,467
Accrued expenses and other current liabilities		5,613			7,283
Accrued interest payable		154			78
Total current liabilities		9,889			10,828
Long-term portion of debt		13,782			13,656
Development derivative liability - related party		65,561			71,037
Total liabilities		89,232			95,521
Total shareholders’ deficit		(52,317	)		(45,295	)
Total liabilities and shareholders’ deficit	$	36,915		$	50,226